Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
about
Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literatureA brief history of the development of antidepressant drugs: from monoamines to glutamateThe safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.Vortioxetine: a New Treatment for Major Depressive Disorder.Vortioxetine (brintellix): a new serotonergic antidepressantVortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trialsMajor depressive disorder: mechanism-based prescribing for personalized medicineVortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorderSafety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.Vortioxetine for the treatment of depression.Vortioxetine: a review of its use in major depressive disorder.Vortioxetine for the treatment of major depressive disorder.A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.Antidepressants and, suicide and self-injury: Causal or casual association?A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder.The Black Book of Psychotropic Dosing and Monitoring.Assessment and management of sexual dysfunction in the context of depression.Vortioxetine: Clinical Pharmacokinetics and Drug Interactions.Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults.
P2860
Q26796436-A35D2D48-4947-4576-88E6-552EE55D78F2Q27028050-FDA5BEBC-1F92-4C7B-8E75-BCA85446D6C7Q31044175-BEEC4A1F-F7D5-4A4E-AB72-77F6A84F7229Q34505568-C94288D6-77E2-4216-AEA6-11123143B487Q34976273-1F2C1B21-9505-49F4-B764-706D1CCD2352Q35280477-FD25828C-E8EE-4C46-B954-BFE3E57786EFQ35284412-DB8E6F08-1908-4664-AE5D-E53459C579D6Q35536869-67004FB1-58B0-41BC-8BA8-4AB9BB2F4011Q35918863-83B19B19-4392-4CB4-B52F-3A39DDAD7C05Q38199987-C29A7A77-4D8E-4141-94C4-D706D09B5200Q38242001-A9F0ED7F-7071-4088-B47B-D22F4A5E8C32Q38244159-5FB9067B-3A72-41AA-859F-0A017F8FAAC7Q38249999-D8A2610D-80FE-46CC-9AA6-CB0C0218582BQ38506798-6A42143C-57F7-4285-87AA-9C10699BE848Q38691860-A6964D6F-1019-4A72-A7E6-18DE08A5010DQ40366493-72ED1FAD-3259-47EF-B2E0-CBBC7BE6B454Q47642128-64369F17-0BDF-48D7-94E4-A338FA096BD0Q47653061-AF4EE70C-B0CF-46E1-8F8B-A976D1F9DE72Q47692041-24991BFF-278E-4A46-9167-2A606FB0A9A2Q47701615-73EA3336-8437-467C-8DF3-BD2C2AD3BDBFQ47760557-4F09C978-C4FB-417C-9E99-923158683209
P2860
Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Safety, tolerability, and effi ...... -dose, 52-week extension study
@ast
Safety, tolerability, and effi ...... -dose, 52-week extension study
@en
Safety, tolerability, and effi ...... -dose, 52-week extension study
@nl
type
label
Safety, tolerability, and effi ...... -dose, 52-week extension study
@ast
Safety, tolerability, and effi ...... -dose, 52-week extension study
@en
Safety, tolerability, and effi ...... -dose, 52-week extension study
@nl
prefLabel
Safety, tolerability, and effi ...... -dose, 52-week extension study
@ast
Safety, tolerability, and effi ...... -dose, 52-week extension study
@en
Safety, tolerability, and effi ...... -dose, 52-week extension study
@nl
P2093
P2860
P1476
Safety, tolerability, and effi ...... -dose, 52-week extension study
@en
P2093
Atul R Mahableshwarkar
Michael Serenko
Mohammed Y Alam
Paula L Jacobsen
Yinzhong Chen
P2860
P356
10.1097/YIC.0000000000000010
P577
2014-01-01T00:00:00Z